MedTrace Logo

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

NCT03673748 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.

Conditions

Interventions

DRUG

Mesenchymal stem cells (MSC)

Endovenous injection of MSV in saline solution

DRUG

Placebo

Endovenous injection of saline solution without cells

Sponsors & Collaborators

  • Hospital del Rio Hortega

    collaborator OTHER

  • Hospital Clínico Universitario de Valladolid

    collaborator OTHER

  • University of Valladolid

    collaborator OTHER

  • Citospin

    collaborator INDUSTRY

  • Red de Terapia Celular

    lead INDUSTRY

Principal Investigators

  • Julia Barbado, MD, PhD · University Hospital Río Hortega, Valladolid, Spain

  • Rosa Conde, PhD · University Hospital Río Hortega, Valladolid, Spain

  • Margarita González-Vallinas, PhD · University of Valladolid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-27
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673748 on ClinicalTrials.gov